Work

Elobixibat Improves Stool/Gas Distribution and Fecal Bile Acids in Older Adults With Chronic Constipation

Year: 2025

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Abstract: Background: Bowel stool and/or gas distribution is an important indicator of bowel function. The mean colonic transverse diameter of the colon and rectum (constipation index) is a stool and/or gas distribution parameter assessed via transabdominal ultrasonography and an indirect indicator of colonic transit time. Elobixibat, an ileal bile acid transporter inhibitor, increases the number of bowel movements in chronic constipation (CC) patients. Aims: To determine whether the constipation index changes following treatment with elobixibat and evaluate the relationship between changes in the constipation index and fecal bile acid concentration. Methods: We conducted a prospective, randomized, double-blind, placebo-controlled trial in 17 CC patients aged ≥ 60 years who were administered elobixibat or placebo daily for 1 week. Changes in stool and/or gas distribution and stool bile acid concentrations were analyzed before and after treatment. Results: Elobixibat, but not placebo, significantly reduced the constipation index. A significant negative correlation was found between the change in the constipation index and the change in total fecal bile acid concentration. Conclusion: JRCT ID: jRCTs061200030; https://rctportal.niph.go.jp/en/detail?trial_id=jRCTs061200030.

Source: JGH Open

DOI: 10.1002/jgh3.70223

Authors: Noriaki Manabe, Emiko Bukeo, Takako Konishi, Maki Ayaki, Minoru Fujita, Ken Haruma

Institution: Kawasaki Medical School

Language: English

Topic: Gastrointestinal motility and disorders

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,400